Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 32810438.
- Also identified by DOI 10.1016/j.cell.2020.08.001 and PMC identifier 7405822.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Coronavirus disease 2019 (COVID-19) is a mild to moderate respiratory tract infection, however, a subset of patients progress to severe disease and respiratory failure. The mechanism of protective immunity in mild forms and the pathogenesis of severe COVID-19 associated with increased neutrophil counts and dysregulated immune responses remain unclear. In a dual-center, two-cohort study, we combined single-cell RNA-sequencing and single-cell proteomics of whole-blood and peripheral-blood mononuclear cells to determine changes in immune cell composition and activation in mild versus severe COVID-19 (242 samples from 109 individuals) over time. HLA-DR<sup>hi</sup>CD11c<sup>hi</sup> inflammatory monocytes with an interferon-stimulated gene signature were elevated in mild COVID-19. Severe COVID-19 was marked by occurrence of neutrophil precursors, as evidence of emergency myelopoiesis, dysfunctional mature neutrophils, and HLA-DR<sup>lo</sup> monocytes. Our study provides detailed insights into the systemic immune response to SARS-CoV-2 infection and reveals profound alterations in the myeloid cell compartment associated with severe COVID-19.
Medical subject headings
- Coronavirus Infections
- Myeloid Cells
- Myelopoiesis
- Pneumonia, Viral